REATA PHARMACEUTICALS INC's ticker is RETA and the CUSIP is 75615P103. A total of 151 filers reported holding REATA PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is 0.53 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2023 | $7,189,811 | +0.0% | 70,516 | -10.8% | 0.00% | -33.3% |
Q1 2023 | $7,186,590 | +266.4% | 79,043 | +53.1% | 0.00% | +200.0% |
Q4 2022 | $1,961,234 | -15.5% | 51,625 | -32.4% | 0.00% | 0.0% |
Q2 2022 | $2,320,000 | -57.7% | 76,351 | -54.4% | 0.00% | -50.0% |
Q1 2022 | $5,482,000 | +141.1% | 167,329 | +94.1% | 0.00% | – |
Q4 2021 | $2,274,000 | -81.2% | 86,222 | -28.3% | 0.00% | -100.0% |
Q3 2021 | $12,093,000 | -8.7% | 120,183 | +28.5% | 0.00% | -20.0% |
Q2 2021 | $13,241,000 | +21.2% | 93,561 | -14.6% | 0.01% | -16.7% |
Q1 2021 | $10,925,000 | +42.6% | 109,574 | +76.8% | 0.01% | +50.0% |
Q4 2020 | $7,661,000 | -43.2% | 61,974 | -55.2% | 0.00% | -50.0% |
Q3 2020 | $13,491,000 | -3.3% | 138,489 | +54.8% | 0.01% | -20.0% |
Q2 2020 | $13,955,000 | +15.0% | 89,446 | +6.4% | 0.01% | -16.7% |
Q1 2020 | $12,131,000 | +847.0% | 84,054 | +1241.2% | 0.01% | +500.0% |
Q4 2019 | $1,281,000 | +442.8% | 6,267 | +127.2% | 0.00% | – |
Q1 2019 | $236,000 | – | 2,758 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
CPMG Inc | 2,896,901 | $288,821,000 | 55.24% |
PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE | 100,000 | $9,970,000 | 15.20% |
Tolleson Wealth Management, Inc. | 108,000 | $10,768,000 | 3.25% |
MADDEN SECURITIES Corp | 34,787 | $3,468,000 | 2.03% |
Biondo Investment Advisors, LLC | 101,204 | $10,090,000 | 2.01% |
LBJ Family Wealth Advisors, Ltd. | 30,368 | $3,027,000 | 1.91% |
Duquesne Family Office | 749,897 | $74,765,000 | 1.65% |
Sofinnova Investments, Inc. | 238,520 | $23,780,000 | 1.43% |
Camber Capital Management LP | 400,000 | $39,880,000 | 1.37% |
Integral Health Asset Management, LLC | 44,000 | $4,387,000 | 1.25% |